USSTOCK.TODAY
Pre-Market
Log in Sign up

Halozyme Therapeutics beats Q3 revenue expectations with $492.97 million

Earnings Whispers · ·by G4L

HALO
HALO Halozyme Therapeutics Inc
$102.92 -0.69%
View chart & analysis →
  1. 1Halozyme Therapeutics' Q3 revenue of $492.97 million exceeded consensus by 2.6%.
  2. 2Halozyme Therapeutics' Q3 Non-GAAP EPS recorded a 3.5% surprise compared to consensus and Earnings Whisper figures.
  3. 3A Dutch court ruled that Merck's Keytruda Qlex infringed on Halozyme's MDASE patent.

So what's the key point?

Halozyme Therapeutics' Q3 revenue was 2.6% higher than what experts expected. A Dutch court ruled that Merck's product infringed on Halozyme's patent.

Source Earnings Whispers · View original ↗

Related 3-line summaries

Comparing Schwab U.S. Small-Cap ETF and JPMorgan BetaBuilders U.S. Small Cap Equity ETF The Motley Fool +1 · Oct 15Delcaths, Praxis Hit 52-Week Highs on Strong Q2 Results Stocktwits +1 · Aug 7Halozyme Signs Licensing Deal with Incyte for Subcutaneous Formulation of INCA033989 InvestorsHub +1 · Jul 21
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news